Tirzepatide
Mounjaro / Zepbound
Tirzepatide is a first-in-class <b>dual GIP + GLP-1 receptor agonist</b> — the molecule behind Mounjaro (type 2 diabetes) and Zepbound (weight management). By hitting two incretin pathways instead of one, it has produced some of the largest weight-loss results of any approved medication. This guide covers how tirzepatide works, what the SURMOUNT trials showed, dosing, side effects, and how it stacks up against semaglutide and retatrutide. Tirzepatide is a prescription medication — this is education, not medical advice.
Tirzepatide quick facts
| Reported research dosing | 0.5mg-15mg |
| Route | Subq |
| Cycle length | As Long As Needed |
| Frequency | 1-2x Weekly (Split Dose) |
| Half-life | ~5 days |
| Forms | Injectable |
| Evidence level | FDA-approved; large human trials |
Proven, FDA-approved, once weekly. The reliable workhorse of the class.
How tirzepatide works
Tirzepatide is a single molecule that activates two incretin receptors at once: GLP-1 (appetite suppression, slowed gastric emptying, glucose-dependent insulin) and GIP (glucose-dependent insulinotropic polypeptide, which adds insulin-sensitizing and metabolic effects). The theory is that the GIP arm complements GLP-1 to produce greater appetite control and glucose improvement than a GLP-1-only drug — with once-weekly dosing.
What the research shows
The SURMOUNT program is the headline evidence. At the highest dose (15 mg weekly), tirzepatide produced average weight loss of about 20–22.5% of body weight over 72 weeks — approaching what was once only achievable with bariatric surgery. Extended follow-up has shown the effect is durable well beyond 72 weeks with minimal attenuation, and 2026 data continues to add cardiovascular, hepatic (liver) and long-term durability evidence.
Approved uses & brand names
Tirzepatide is sold as Mounjaro (type 2 diabetes) and Zepbound (weight management, and more recently obstructive sleep apnea in obesity). Both are once-weekly subcutaneous injections. Whether it's appropriate for a person is a decision for a licensed prescriber.
Dosing & titration (as prescribed / studied)
Approved tirzepatide is titrated gradually — commonly starting around 2.5 mg once weekly and stepping up every 4 weeks through 5, 7.5, 10, 12.5 up to 15 mg as tolerated. As with all incretins, the gradual ramp exists to limit gastrointestinal side effects, which are most pronounced during escalation. Actual dosing must be set and supervised by a prescriber; these figures summarize the studied/approved schedule for education only.
Side effects
The most common side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation — generally mild-to-moderate and most noticeable while escalating the dose. As with other incretins there are rarer, more serious considerations (gallbladder, pancreatitis, and a rodent thyroid C-cell tumor boxed warning), which is why it's prescription-only and medically supervised.
Tirzepatide vs semaglutide vs retatrutide
Semaglutide hits one pathway (GLP-1, ~15–21%). Tirzepatide hits two (GLP-1 + GIP, ~20–22.5%). Retatrutide hits three (adds glucagon) and has shown even larger trial results, but remains investigational. Broadly, adding pathways has meant more weight loss — at the cost of newer, less mature long-term data as you go.
Important safety & legal note
Tirzepatide is a prescription medication and should only be used under a licensed provider's care. The FDA has cautioned about unapproved and compounded GLP-1/GIP products sold outside the regulated supply chain. Nothing here is a recommendation to obtain or use tirzepatide outside a legitimate prescription.
Where to get Tirzepatide
Buy Tirzepatide at AminoWell USA →Tirzepatide reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Tirzepatide
Graded by what exists behind each claim.
✅ Clinically validated
- The strongest weight-loss trial data of any approved drug. FDA-approved as Mounjaro and Zepbound; SURMOUNT-1 produced ~20.9% mean body-weight loss at the 15 mg dose over 72 weeks, and SURPASS showed HbA1c reductions exceeding semaglutide head-to-head.
- SURMOUNT-OSA later showed clinically meaningful improvement in obstructive sleep apnea, which is a second organ-level outcome rather than a surrogate.
📊 Correlative data
- Real-world use reports the same GI profile as semaglutide with, anecdotally, somewhat better tolerability at equivalent weight loss — consistent with the GIP component, though nobody has isolated that.
- Same discontinuation problem, same lean-mass caveat, same warning about compounded supply. The published trials describe the branded molecule under supervision.
🧪 Theoretical / extrapolated
- A dual GIP and GLP-1 receptor agonist. GIP was long dismissed as metabolically unhelpful in obesity, and the working hypothesis is that agonizing it alongside GLP-1 improves adipose insulin sensitivity and blunts the nausea that limits GLP-1 dosing — which would explain both the larger effect and the tolerability.
- The dual mechanism predicts the ceiling too: this is still appetite-led weight loss, so without resistance training the composition of what is lost is no better than with a single agonist.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Tirzepatide actually does
Tirzepatide is a 39-residue synthetic peptide built on the GIP backbone, not the GLP-1 one, and that is the fact the whole molecule follows from. It carries an aminoisobutyric acid at positions 2 and 13 — a non-natural residue that dipeptidyl peptidase-4 cannot cut, which is what turns a peptide with a two-minute life into one with a weekly dose — and a C20 fatty diacid attached through a linker to the lysine at position 20. That fatty acid is not a delivery trick. It binds serum albumin, and albumin's own long residence in the circulation becomes the peptide's.
So the ~5 day half-life is an albumin number, not a peptide number. Population pharmacokinetic modeling puts it at approximately 5 days and finds that sustained exposure with once-weekly subcutaneous dosing follows directly from it, with no dose adjustment needed for demographics or subpopulations Schneck 2024. The peptide spends most of its time reversibly parked on albumin, and only the free fraction engages receptors.
Both receptors are class B G-protein-coupled receptors and both raise cyclic AMP, but the molecule is not balanced between them. It behaves as a full agonist at the GIP receptor and as a weaker, biased agonist at the GLP-1 receptor — reduced beta-arrestin recruitment relative to native GLP-1, which slows receptor internalization and keeps signaling at the cell surface for longer. That imbalance is the design, and it is why tirzepatide is not simply “semaglutide plus GIP”.
And here is the fact that makes GIP the most interesting receptor in metabolic medicine right now: agonizing it and BLOCKING it both produce weight loss in humans, and nobody has resolved why. Two independent drug-development programs were built on opposite pharmacology at the same receptor, and both produced clinical signals. The competing explanations — that chronic agonism functionally desensitizes the receptor, that central and peripheral GIP receptor populations do different things, that GIP receptor agonism mainly buys tolerability rather than efficacy — are laid out and weighed in the primary literature Douros 2025 Campbell 2021. The Vault should say this plainly: the GIP arm of this drug works, and the field does not agree on the mechanism.
Cell, rodent, human — and where it stops
Step one, in people, because this molecule skipped the part of the chain where most Vault compounds stop. SURMOUNT-1 randomized adults with obesity and no diabetes and measured body weight at week 72: -15.0% at 5 mg, -19.5% at 10 mg, -20.9% at 15 mg, against -3.1% on placebo, with 85%, 89% and 91% of participants losing at least 5% against 35% on placebo, all p<0.001 Jastreboff 2022. There is no extrapolation to do here. This is a human randomized result at the endpoint people actually want.
Step two, the tolerability arithmetic, which is where the practical argument lives. Across SURMOUNT-1 to -4, gastrointestinal adverse events occurred in 27.8% to 72.8% of tirzepatide arms against 12.2% to 32.5% on placebo — a wide range because it scales with dose and titration speed. The important result is the mediation analysis: nausea, vomiting, diarrhea and dyspepsia together accounted for up to 3.1% of total weight reduction Rubino 2025. The weight loss is not sickness. That single number refutes the commonest objection to the whole class, and it is not on this page today.
Step three, what happens when it stops — and this is the part the card's ‘as long as needed’ skips over. A post hoc analysis of SURMOUNT-4 looked at 308 participants by how much weight they regained after withdrawal. Those with the greatest regain (at least 75%) saw waist circumference rise by 14.7 cm and systolic blood pressure by 10.4 mm Hg; those who regained less than 25% showed changes not significantly different from week 36 Horn 2025. Read that carefully, because it cuts both ways: the cardiometabolic loss tracks the weight regain rather than the stopping itself. Hold the weight and you hold the benefit.
The obstacle, named. Every number above comes from a supervised trial with a fixed titration schedule and a once-weekly dose. The card here describes 1–2x weekly split dosing, which no registration trial used. Splitting a weekly dose halves the peak concentration without changing weekly exposure, and since the gastrointestinal events plausibly track peak rather than average, split dosing is a mechanistically reasonable idea with zero published data behind it. That gap is the honest edge of what is known.
Tirzepatide pharmacokinetics — how much of it actually gets in
The card says ~5 days. That number is right, it is measured, and what it implies is more interesting than the number.
What clears it, and what does not. Tirzepatide is a peptide, so it is broken down by proteolysis into amino acids throughout the body rather than by a cytochrome. The cleanest evidence that renal clearance is not the route comes from a dedicated study in renal impairment: exposure was similar across renal impairment groups and healthy subjects, with 90% confidence intervals for AUC and Cmax ratios spanning unity except for a 25–29% increase in AUC in the moderate impairment group, and the conclusion was no clinically relevant effect and no dose adjustment required Urva 2021. A drug whose clearance barely notices the kidney is a drug that is not being filtered, which is exactly what albumin binding predicts.
The oral barrier, and why the injection is not optional. This is a 39-residue peptide. Swallowed, it meets pepsin in the stomach, trypsin and chymotrypsin from the pancreas, and brush-border aminopeptidases in the small intestine, all before first-pass metabolism becomes relevant. Oral bioavailability of an unprotected peptide this size is a rounding error, which is why the route is subcutaneous and why the oral members of the class are small-molecule agonists rather than peptides.
The arithmetic a weekly schedule implies, done out loud. With a 5-day half-life and weekly dosing, roughly 40% of the previous dose is still present when the next one is given, so steady state is reached after about four to five weeks — and that, not tolerance, is why a dose that felt fine in week one can feel different in week four at the same milligrams. It is also why titration steps are spaced four weeks apart in the trials: you are waiting for the previous step to finish accumulating before judging it.
The split-dose question, computed rather than asserted. Halving the dose and giving it twice weekly leaves weekly exposure unchanged and cuts the peak-to-trough swing roughly in half. If gastrointestinal events track peak concentration, splitting should reduce them; if they track average exposure, splitting changes nothing. Those two hypotheses make different predictions and the published once-weekly event rates Rubino 2025 are the comparator anyone running it should be measuring against.
What would have to be true, and how you would know it was not
Three predictions with markers, directions and windows. The third is the one that argues against how the compound is usually used.
1. Lipase and amylase should rise modestly and stay in a stable band, and that is not pancreatitis. Incretin agonists raise pancreatic enzymes in a large fraction of users without clinical consequence, and the rise plateaus. Draw lipase and amylase at baseline and at 12 weeks. Prediction: a modest rise that then holds steady. What matters is the shape, not the value — a plateau is the expected pharmacology; a value that keeps climbing, or one accompanied by pain, is a different conversation and belongs with a clinician rather than a page.
2. Fasting insulin should fall further and faster than HbA1c, and the GIP arm predicts that gap. GIP is insulinotropic in a glucose-dependent way and it improves adipose insulin sensitivity, so the earliest measurable change should be in how much insulin is needed rather than in the glucose average. Draw fasting insulin and HbA1c at baseline, 12 weeks and 24 weeks. Prediction: insulin falls first and proportionally more. If HbA1c moves first, the effect is being driven by intake reduction alone, which is the GLP-1 arm doing the work.
3. The prediction that cuts against the way it is used: stop it and the cardiometabolic numbers track the weight, not the drug. In SURMOUNT-4's withdrawal analysis, the participants who regained least showed changes not significantly different from where they started the withdrawal, and the ones who regained most lost 14.7 cm of waist and 10.4 mm Hg of systolic pressure back Horn 2025. So the falsifiable claim is: draw a lipid panel and ApoB, with waist and blood pressure, at the moment of stopping and again at 6 months. If weight is held and those numbers still deteriorate, the drug was doing something beyond weight loss and the field does not currently think it was. If they hold, the honest framing is that this is a weight drug and the maintenance problem is a weight problem.
What nobody has tested yet
Four questions with no published answer, all of them within reach of the people already taking this.
Nobody has published a split-dose trial. Every SURMOUNT and SURPASS trial used once weekly. The card here recommends up to twice weekly. Whether halving the peak reduces the nausea rates measured across SURMOUNT-1 to -4 Rubino 2025 is an ordinary crossover question with an obvious endpoint and no data at all.
Nobody has separated the GIP arm's contribution in a human. The paradox is live: agonists and antagonists at the same receptor both produce weight loss Douros 2025. A three-arm trial of tirzepatide, a matched GLP-1 mono-agonist and a GIP-receptor modulator, powered on tolerability rather than weight, would answer the question the whole field is arguing about. It has not been run.
Nobody has measured lean mass systematically at these rates of weight loss. Twenty percent of body weight in 72 weeks Jastreboff 2022 is a rate at which body composition, not scale weight, is the meaningful variable. DEXA at baseline, 6 and 12 months is unremarkable technology and it is not standard practice in this population.
Nobody has tested whether a reduced maintenance dose preserves the benefit. The withdrawal data shows what full stopping does Horn 2025. The question everyone actually faces — whether a quarter dose holds the weight — sits between the two published conditions and has never been studied.
Tirzepatide — its own safety story, not its class's
This molecule's own risk story is gastrointestinal, pancreatic-adjacent and, above all, about what happens when it stops. The generic class block below does not carry the numbers.
The gastrointestinal profile, quantified. Across the four SURMOUNT trials, GI adverse events ran 27.8% to 72.8% on tirzepatide against 12.2% to 32.5% on placebo Rubino 2025. That is not a footnote — at the top of the range it is most people. The mitigating fact from the same analysis is that those symptoms accounted for at most 3.1% of the weight reduction, so slowing titration to control them costs almost nothing in efficacy. That is the single most useful dose-management fact about this drug and it comes from a mediation analysis, not from advice.
Why gastric emptying matters beyond nausea. The mechanism that produces satiety is a genuinely slowed stomach, and a slowed stomach is a procedural consideration for anesthesia and endoscopy, and a reason oral medicines taken at the same time may be absorbed on a different schedule than expected. Anyone with a procedure booked needs that on the pre-operative form; it is a fact about the pharmacology, not a scare.
The kidney, stated the right way round. The drug itself is not renally cleared and needs no adjustment for impaired kidney function Urva 2021. The risk to the kidney is indirect and entirely mechanical: vomiting and reduced intake cause volume depletion, and volume depletion is what injures kidneys. So the renal risk of this drug is a hydration problem, and it is managed as one.
The discontinuation risk, which no other page in this class quantifies. Greatest weight regain after withdrawal came with a 14.7 cm rise in waist circumference and a 10.4 mm Hg rise in systolic blood pressure; the smallest regain group showed no significant change Horn 2025. The mechanistic reading is that these are consequences of the fat coming back rather than of the drug leaving — which makes an exit plan part of the protocol rather than an afterthought, and makes the maintenance question the real clinical question.
And the legal fact that is part of the safety picture. This is a prescription medicine. Compounded and gray-market versions are not the molecule tested in SURMOUNT, are not assayed by the buyer, and are the one variable that makes every number on this page inapplicable. Nothing here is medical advice or a recommendation for use.
Sources read for this page
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 2022 · PMID 35658024
- Rubino DM, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes, Obesity and Metabolism 2025 · PMID 39789843
- Urva S, et al. Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide. Clinical Pharmacokinetics 2021 · PMID 33778934
- Schneck K, et al. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. CPT: Pharmacometrics and Systems Pharmacology 2024 · PMID 38356317
- Douros JD, et al. The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs. Journal of Clinical Medicine 2025 · PMID 40507574
- Campbell JE. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms. Molecular Metabolism 2021 · PMID 33290902
- Horn DB, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Internal Medicine 2025 · PMID 41284285
Tirzepatide — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- These slow gastric emptying and act on hypothalamic and brainstem appetite centers. Almost everything that goes wrong follows from the gastric emptying, not from anything exotic: nausea, early fullness, reflux, constipation, and — when someone titrates faster than their gut adapts — vomiting.
- The composition risk is the one nobody warns about. Appetite suppression does not discriminate. It suppresses the appetite for protein too, and in a deficit without adequate protein and a resistance stimulus a meaningful share of the loss is lean mass. That lowers the maintenance intake you eventually eat back into, which is the mechanism behind most of the rebound stories.
- Slowed emptying also delays absorption of anything else taken by mouth — a pharmacokinetic consequence rather than a drug interaction, but it matters for anything time-critical.
What has actually been reported
- GI effects are extremely common and mostly settle over weeks. Gallbladder problems are a recognized signal, and rapid weight loss of any cause raises gallstone risk — the drug is not doing something unusual, it is doing rapid weight loss well.
- Pancreatitis is reported and rare. The presentation to know is severe upper abdominal pain radiating to the back, usually with vomiting.
- A thyroid C-cell tumor signal exists in rodents and has not been demonstrated in humans; it is why the labeled contraindication for medullary thyroid carcinoma and MEN2 exists.
How to reduce the risk
Same mechanism as the prediction.
- Follow the titration schedule even if you feel fine. It exists for gut adaptation, not for legal cover. Almost everyone who quits in the first month escalated faster than their stomach could keep up.
- Hit your protein target first at every meal, before anything else on the plate. This is the single highest-leverage habit on the drug — 1.6–2.2 g/kg, and eat it while you still have the appetite to.
- Lift while you are on it. The compound handles intake; resistance training is the only thing handling what you keep.
- Aim for 0.5–1% of bodyweight per week, deliberately. The drug removes the hunger signal that would normally stop you going too hard, so the rate has to be a decision rather than a by-product.
- Fiber and electrolytes from day one, not from week four when constipation has already made up your mind about the drug.
- If nausea is winning, step back one dose rather than quitting the class. Almost nobody needs to be at the top of the range.
What it does to your bloodwork
A fact about the assay.
- HbA1c and fasting glucose should improve — that is the drug working, and it is the cleanest confirmation you have.
- Rapid loss moves lipids, liver enzymes and uric acid transiently. A wobble at 8 weeks into aggressive loss is usually the loss, not a new problem — but it is a reason to have the baseline.
- Worth a thyroid panel and a lipid panel before starting, simply so a later result has something to be compared against.
Don't run this if
- Personal or family history of medullary thyroid carcinoma, or MEN2.
- Previous pancreatitis.
- Active gastroparesis — you would be adding a drug whose main action is the thing already wrong.
The honest unknown
- What happens to body composition over repeated multi-year cycles of loss and regain on and off these drugs. Weight is well studied; the muscle-to-fat ratio of what comes back is not.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Any time — but the same day each week
With a half-life measured in days you are dosing into a standing level, so the hour is irrelevant and the consistency is not. Pick a day and hold it; drifting the interval is what produces the peaks and troughs people mistake for the drug not working.
Food makes no meaningful difference at this half-life.
From half-life and route, not a dosing trial.
Tirzepatide — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Tirzepatide moves on your bloodwork
Expected direction, not a measured one.
- HbA1c (Hemoglobin A1c) — ↓ expected to fall
Falling HbA1c is the compound working. Expect it.
What to do: Baseline and 12 weeks. It moves slowly by design — a 4-week retest tells you very little. - Fasting Insulin — ↓ expected to fall
Insulin sensitivity improves as weight falls and the incretin effect restores first-phase insulin release.
What to do: Useful alongside HbA1c; the two together read the trend properly. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to fall
Triglycerides in particular fall with weight loss and improved insulin sensitivity.
What to do: Re-check at 12 weeks rather than chasing early numbers. - Lipase — ↑ expected to rise
Lipase and amylase can rise without pancreatitis on this class. An isolated mild elevation in someone with no symptoms is common.
What to do: Severe, persistent abdominal pain radiating to the back is the thing that matters, not the number. Symptoms decide, not a mild enzyme rise. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Rapid weight loss and reduced intake shift electrolytes and kidney markers; dehydration from nausea or vomiting shows up here first.
What to do: Worth a baseline. If you have been vomiting, this is the panel that catches the consequence. - Ferritin — ↓ expected to fall
Not the drug — the eating. Sharply reduced intake drops iron, B12 and protein intake with it, and this is the most commonly missed consequence of a good response.
What to do: Check ferritin and B12 at 12 weeks. Muscle loss and hair shedding on a GLP-1 is very often a nutrition problem wearing a drug's name.
The pattern with this class is that the frightening-looking numbers (lipase) are usually fine and the boring ones (ferritin, B12) are where the real damage happens.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Tirzepatide
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | The baseline you can't reconstruct later |
| Fasting Insulin | Falls as the drug works |
| Lipase | Pancreatitis is rare but serious — catch it early |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes during rapid loss |
| Complete Blood Count (CBC) with Differential | Muscle and nutrition status over a long taper up |
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel covers these in one order — 11 markers, $148.05 with the discount applied.
Check results you already have → · All 103 markers A–Z
Tirzepatide — frequently asked questions
What is tirzepatide?
Tirzepatide is a once-weekly dual GIP + GLP-1 receptor agonist medication, sold as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea).
How does tirzepatide work?
It activates two incretin receptors at once — GLP-1 (appetite, gastric emptying, insulin) and GIP (insulin-sensitizing, metabolic) — which together drive stronger appetite control and glucose improvement than GLP-1 alone.
How much weight can you lose on tirzepatide?
In the SURMOUNT trials, the 15 mg weekly dose produced about 20–22.5% average weight loss over 72 weeks, with durable effects on longer follow-up. Individual results vary.
How is tirzepatide dosed?
Approved regimens titrate gradually, commonly from 2.5 mg weekly up through 5, 7.5, 10, 12.5 to 15 mg every ~4 weeks as tolerated, always prescriber-supervised. The gradual ramp limits GI side effects.
What are the side effects of tirzepatide?
Most commonly GI — nausea, diarrhea, vomiting, constipation — mild-to-moderate and worst during dose escalation. Rarer serious risks exist, which is why it's prescription-only and supervised.
Tirzepatide vs semaglutide — which is stronger?
In trials, tirzepatide (dual GIP/GLP-1) produced larger average weight loss than semaglutide (GLP-1 only). Which is appropriate for a person is a medical decision, not a one-size-fits-all answer.
Is tirzepatide FDA-approved?
Yes — as Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea). The FDA has warned about unapproved/compounded versions sold outside the regulated supply chain.
References & further reading
- Tirzepatide (Zepbound, Mounjaro): dosage & side effects (Drugs.com)
- GLP-1/GIP dual agonist tirzepatide — clinical overview (Pharmacy Times)
Tirzepatide inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Tirzepatide is used for
Tirzepatide appears under 2 goals in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
Tirzepatide is the appetite arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.